Literature DB >> 8221646

Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma.

D N Shapiro1, J E Sublett, B Li, J R Downing, C W Naeve.   

Abstract

Alveolar rhabdomyosarcoma, a malignant tumor of skeletal muscle, is characterized by a chromosomal translocation, t(2;13)(q35;q14). This translocation is associated with a structural rearrangement of the gene encoding PAX3, a presumed transcriptional regulator expressed exclusively during embryogenesis. The breakpoint results in a fusion between PAX3 and a gene provisionally named ALV, a novel member of the forkhead family of transcription factors. In PAX3-ALV, the structural integrity of both PAX3 DNA-binding regions, the paired box and homeodomain, are retained while the putative transcriptional activation domain of PAX3 is replaced by the bisected forkhead DNA-binding domain of ALV. Formation of chimeric transcription factors has now been implicated in diverse human tumors of myogenic, hematopoietic, neuroectodermal, and adipocytic origin, suggesting that transcriptional deregulation is a common mechanism of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221646

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  100 in total

1.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

3.  Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.

Authors:  R J Davis; F G Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

5.  Isolation of putative FOXO1 genomic elements using an improved in vitro technique to isolate genomic regulatory sequences.

Authors:  Alpa Sidhu; Patrick J Miller; Andrew D Hollenbach
Journal:  Gene       Date:  2010-03-23       Impact factor: 3.688

6.  Microarray analysis of promoter methylation in lung cancers.

Authors:  Masayuki Fukasawa; Mika Kimura; Sumiyo Morita; Kenichi Matsubara; Sumitaka Yamanaka; Chiaki Endo; Akira Sakurada; Masami Sato; Takashi Kondo; Akira Horii; Hiroyuki Sasaki; Izuho Hatada
Journal:  J Hum Genet       Date:  2006-01-25       Impact factor: 3.172

7.  In vitro differentiation and proliferation in a newly established human rhabdomyosarcoma cell line.

Authors:  A Ogose; T Motoyama; T Hotta; H Watanabe
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Authors:  Irina Lagutina; Simon J Conway; Jack Sublett; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable.

Authors:  K Monica; D P LeBrun; D A Dedera; R Brown; M L Cleary
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

Review 10.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.